Company Description

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.

Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies.

The company was incorporated in 2021 and is based in South San Francisco, California.

CERo Therapeutics Holdings, Inc.

Country	United States
Founded	2017
Industry	Biotechnology
Sector	Healthcare
Employees	9
CEO	Christopher Ehrlich

Contact Details

Address: 201 Haskins Way, Suite 230 South San Francisco, California 94080 United States
Phone	215 731 9450
Website	cero.bio

Stock Details

Ticker Symbol	CERO
Exchange	NASDAQ
Stock Type	Common Stock
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001870404
ISIN Number	US71902K1051
Employer ID	87-1088814
SIC Code	2836

Key Executives

Name	Position
Christopher B. Ehrlich M.B.A.	Chief Executive Officer and Chair
Brian G. Atwood	President and Director
Dr. Lawrence Corey M.D.	Co-founder and Head of Scientific Advisory Board
Andrew Albert Kucharchuk M.B.A.	Chief Financial Officer and Director
Dr. Kristen Pierce Ph.D.	Chief Development Officer and Director

Latest SEC Filings

Date	Type	Title
Jan 21, 2025	8-K	Current Report
Jan 21, 2025	S-1/A	[Amend] General form for registration of securities under the Securities Act of 1933
Jan 14, 2025	424B3	Prospectus
Jan 14, 2025	424B3	Prospectus
Jan 14, 2025	424B3	Prospectus
Jan 14, 2025	424B3	Prospectus
Jan 10, 2025	8-K	Current Report
Jan 7, 2025	424B3	Prospectus
Jan 7, 2025	424B3	Prospectus
Jan 7, 2025	424B3	Prospectus

View All SEC Filings